Oct. 17 at 2:50 PM
$PHGE
BiomX Inc reported encouraging FDA feedback that could expand development pathways for its bacteriophage therapy BX004 in cystic fibrosis. The company said it has addressed all FDA queries related to its delivery device, with the Phase 2b trial on track for topline results in Q1 2026.
https://prismmarketview.com/biomx-announces-fda-feedback-supporting-expanded-development-pathways-for-bx004-in-cystic-fibrosis/